Henning Helmke
Corporate Officer/Principal bei Göhmann Rechtsanwälte Partnergesellschaft
Profil
Henning Helmke is currently a Member at Göhmann Rechtsanwälte Partnergesellschaft.
He previously worked as a Director-Supervisory Board at KeyNeurotek Pharmaceuticals AG.
Mr. Helmke has a graduate degree from the University of Gottingen and undergraduate degrees from Eberhard Karls Universität Tübingen, the University of Geneva, and Université Paris 8 Vincennes Saint-Denis.
Aktive Positionen von Henning Helmke
| Unternehmen | Position | Beginn |
|---|---|---|
| Göhmann Rechtsanwälte Partnergesellschaft | Corporate Officer/Principal | 14.05.2010 |
Ehemalige bekannte Positionen von Henning Helmke
| Unternehmen | Position | Ende |
|---|---|---|
KeyNeurotek Pharmaceuticals AG
 KeyNeurotek Pharmaceuticals AG Pharmaceuticals: OtherHealth Technology KeyNeurotek Pharmaceuticals AG is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal and autoimmune diseases. KeyNeurotek’s drug portfolio covers the entire drug development chain from research stage to advanced clinical development. At present, two compounds are in clinical development, KN38-7271 and KN203, both addressing significant markets such as traumatic brain injury, TBI, stroke, and urinary incontinence/overactive bladder. The company’s product development is based on its proprietary technology platform, which has been specifically tailored to diseases of the central nervous system, TELOMICS. KeyNeurotek was founded by Dr Frank Striggow, Frank Baumgart, Prof Dr Klaus G. Reymann and Prof Dr Henning Scheich in May 2000. The company is located in Magdeburg, Germany. | Direktor/Vorstandsmitglied | 03.08.2011 |
Ausbildung von Henning Helmke
| Eberhard Karls Universität Tübingen | Undergraduate Degree |
| University of Geneva | Undergraduate Degree |
| Université Paris 8 Vincennes Saint-Denis | Undergraduate Degree |
| University of Gottingen | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
KeyNeurotek Pharmaceuticals AG
KeyNeurotek Pharmaceuticals AG Pharmaceuticals: OtherHealth Technology KeyNeurotek Pharmaceuticals AG is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal and autoimmune diseases. KeyNeurotek’s drug portfolio covers the entire drug development chain from research stage to advanced clinical development. At present, two compounds are in clinical development, KN38-7271 and KN203, both addressing significant markets such as traumatic brain injury, TBI, stroke, and urinary incontinence/overactive bladder. The company’s product development is based on its proprietary technology platform, which has been specifically tailored to diseases of the central nervous system, TELOMICS. KeyNeurotek was founded by Dr Frank Striggow, Frank Baumgart, Prof Dr Klaus G. Reymann and Prof Dr Henning Scheich in May 2000. The company is located in Magdeburg, Germany. | Health Technology |
| Göhmann Rechtsanwälte Partnergesellschaft |
